Literature DB >> 18036733

Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.

Jeong-Min Cho1, Sarala Manandhar, Hyang-Rim Lee, Hyun-Min Park, Mi-Kyoung Kwak.   

Abstract

The treatment of alkylating cytotoxic drug cisplatin is often limited by high incidence rate of resistance. In the present study, the potential involvement of the transcription factor Nrf2 in determination of cisplatin cytotoxicity has been investigated. Nrf2-deficient murine embryonic fibroblasts showed increased cell death, cytotoxicity, and apoptosis in response to cisplatin treatment compared to wild-type cells. Cisplatin-resistant human ovarian cancer SK-OV cells, which are retaining 25-fold higher levels of GSH than murine fibroblasts, could be sensitized by inhibition of Nrf2. Transfection with Nrf2 siRNA into SK-OV cells resulted in severe degree of GSH depletion and exacerbated cytotoxicity following cisplatin treatment compared to scrambled RNA control. In conclusion, we propose that the Nrf2 pathway, which plays a protective role in normal cells, can be a potential target to control cancer cell resistance to oxidants, cytotoxic chemicals, and radiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036733     DOI: 10.1016/j.canlet.2007.10.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  64 in total

1.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer.

Authors:  Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Authors:  Luisa M Solis; Carmen Behrens; Wenli Dong; Milind Suraokar; Natalie C Ozburn; Cesar A Moran; Alejandro H Corvalan; Shyam Biswal; Stephen G Swisher; B Nebiyou Bekele; John D Minna; David J Stewart; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

3.  Stressed tumor cell, chemosensitized cancer.

Authors:  Erik A C Wiemer
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

4.  Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells.

Authors:  Young Bin Hong; Hyo Jin Kang; Sun Young Kwon; Hee Jeong Kim; Kun Young Kwon; Chi Heum Cho; Jong-Min Lee; Bhaskar V S Kallakury; Insoo Bae
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

5.  Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.

Authors:  Monique G P van der Wijst; Christian Huisman; Archibold Mposhi; Gerard Roelfes; Marianne G Rots
Journal:  Mol Oncol       Date:  2015-03-19       Impact factor: 6.603

6.  Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line.

Authors:  Ping Xiong; Yu-xuan Li; Yun-tao Tang; Hong-gang Chen
Journal:  Protein J       Date:  2011-10       Impact factor: 2.371

7.  Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.

Authors:  Dongmei Ren; Nicole F Villeneuve; Tao Jiang; Tongde Wu; Alexandria Lau; Henry A Toppin; Donna D Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-04       Impact factor: 11.205

8.  Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells.

Authors:  Longfei Huo; Chia-Wei Li; Tzu-Hsuan Huang; Yung Carmen Lam; Weiya Xia; Chun Tu; Wei-Chao Chang; Jennifer L Hsu; Dung-Fang Lee; Lei Nie; Hirohito Yamaguchi; Yan Wang; Jingyu Lang; Long-Yuan Li; Chung-Hsuan Chen; Lopa Mishra; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

9.  Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.

Authors:  Ling-Jie Bao; Melba C Jaramillo; Zhen-Bo Zhang; Yun-Xi Zheng; Ming Yao; Donna D Zhang; Xiao-Fang Yi
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation.

Authors:  Hyang-Rim Lee; Jeong-Min Cho; Dong-ha Shin; Chul Soon Yong; Han-Gon Choi; Nobunao Wakabayashi; Mi-Kyoung Kwak
Journal:  Mol Cell Biochem       Date:  2008-06-28       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.